Non-Alcoholic Fatty Liver Disease, Hyperuricemia
Conditions
Keywords
Fatty liver disease, Hyperuricemia, Allopurinol, Febuxostat
Brief summary
Metabolic associated fatty liver disease (MAFLD) is the most common and harmful chronic liver disease, and it is increasingly diagnosed in many developed and developing countries. Previous studies suggested a significant association between hyperuricemia and MAFLD and that hyperuricemia plays a causal role in the development of MAFLD. Xanthine oxidase is a key enzyme in uric acid metabolism, and It thus can be considered as is a therapeutic target for MAFLD, so long-term urate-lowering therapy may play a role in amelioration of MAFLD by controlling uric acid levels. So, this study is conducted to assess the effect of controlling hyperuricemia using different xanthine oxidase inhibitors on amelioration of MAFLD.
Detailed description
The aim of this study is to evaluate the effect of urate lowering therapy on improvement of steatosis in metabolic associated fatty liver disease (MAFLD) patients with hyperuricemia, by comparing two xanthine oxidase inhibitors allopurinol (100 mg/day), versus Febuxostat (40 mg/day), versus lifestyle intervention. Primary Outcome: Regression of hepatic steatosis. Secondary Outcome: Improvement of Serum uric acid and incidence of hepatotoxicity. Study design: This study is a prospective, interventional three arm study. Setting: Patients will be recruited from the National Hepatology and Tropical Medicine Research institute, Cairo, Egypt.
Interventions
DRUGAllopurinol (100 mg/day) plus lifestyle intervention
participants accept allopurinol treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
DRUGFebuxostat 40 mg plus lifestyle intervention
participants accept Febuxostat treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
BEHAVIORALLife style intervention
According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
Sponsors
Ain Shams University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
A total of 90 subjects are enrolled in this study. After the initial screening, the subjects were randomly divided into the control group and the drug treatment group. The control group was given lifestyle intervention for 24 weeks, and the experimental group was given febuxostat oral therapy or allopurinol oral therapy on the basis of lifestyle intervention.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Ages 18-65. * Males and Females * Metabolic syndrome according to the NCEP ATP III definition \[13\]: present of three or more of the following five criteria are met: * Waist circumference over 40 inches (men) or 35 inches (women), Central obesity - defined as waist circumference ≥ 102 cm for Men and ≥ 88 cm for women * Blood pressure over 130/85 mmHg, * Basting triglyceride (TG) level over 150 mg/dl, * Fasting high-density lipoprotein (HDL) cholesterol level less than 40 mg/dl (men) or 50 mg/dl (women), * Fasting blood sugar over 100 mg/dl. * Serum uric acid levels of \> 420μmol/L (\>7 mg/dL) in men and \>360 μmol/L (\>6 mg/dL) women.
Exclusion criteria
* Renal insufficiency defined by serum creatinine \> 2.0 mg/dl. * Patients with obvious abnormal liver function: serum transaminase (ALT, AST, one of them) exceed 2 times the upper limit of normal reference value. * Have a history of viral hepatitis, or serological examination suggests hepatitis virus infection, or have a history of other liver diseases. * Complementation with diabetes, or fasting blood glucose \>7.8mmol/L, or HbA1c \>7.5%. * Severe hypertension, blood pressure ≥ 160/100 mmHg. * A history of allergy to febuxostat and allopurinol; in the acute active phase of gout. * Drinking equivalent to alcohol intake ≥30g/d(male), ≥20g/d(female). * Complicated coronary heart disease. * Cardiac dysfunction (cardiac function grade 2 or above). * Patients with asthma and other respiratory diseases. * Intestinal diseases such as inflammatory bowel disease. * Any history of systemic malignancy in the past 5 years. * Use of uric-lowering drugs in the 4 weeks before screening: febuxostat, allopurinol, benzbromarone. * Morbid obesity (BMI\>37.5kg/m2). * Triglyceride ≥5.0 mmol/L was found to be significantly abnormal in baseline examination. * had received systemic hormone or immunosuppressive therapy within 3 months prior to screening or expected to receive hormone or immunosuppressive therapy in the future. * Use of other drugs affecting uric acid metabolism were adjusted within 4 weeks before screening: losartan, fenofibrate, irbesartan, thiazide diuretics, loop medullar diuretics, compound antihypertensive agents containing diuretics. Other drugs that may affect liver fat content were taken within 4 weeks before screening. * Women who are lactating or pregnant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in hepatic steatosis . | 3 months | FibroScan instrument measures fibrosis (scarring) and steatosis (fatty changes) in your liver. Fatty changes are when fat builds up in your liver cells. FibroScan steatosis result (CAP score): decibels per meter(dB/M). it ranges from 100 to 400 dB/m. The fibrosis result is measured in kilopascals (kpa). It is normaly between 2 and 6 kpa. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum uric acid. | three months | change in serum uric milligrams/deciliter (mg/dl) in hyperuricemia patients. Normal values are 1.5 to 6.0 (mg/dl). |
Countries
Egypt
Outcome results
None listed